Applied Digital (APLD) is positioned at the heart of the AI-driven data center infrastructure boom, with long-term leases fueling explosive growth. APLD's recent contracts provide strong revenue visibility, short payback periods, and minimal financing needs, supporting a credible path to $100 per share. With $3 billion in projected annual revenue by 2030 and robust margins, APLD offers high-visibility upside from its current ~$23.50 price, justifying a Buy rating.

Melissa Armo says markets can continue selling action into and after Nvidia's (NVDA) earnings. If investors don't react positively to the report, she expects the stock to gap down and add to already bearish sentiment currently eating at the A.I.

Nvidia Corporation remains a top AI chip play, with strong demand and robust growth projections ahead of its FQ3 '26 earnings report this week. The AI GPU company is expected to post significant revenue and EPS growth, with consensus estimates pointing to a massive sequential jump and continued outperformance. Despite market fears of an AI bubble, NVDA stock trades at reasonable multiples relative to its growth, lacking the premium valuation typical of bubbles.

FPAG's top five performers contributed 5.94% and 11.17% to its returns in the previous quarter and twelve months, respectively. bottom five detracted 2.83% and 5.01% from its returns in the previous quarter and twelve months, respectively. Despite anxiety about Alphabet's future that has colored investors' views of the company, its stock price has risen approximately 74% since our initial purchases.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that S&P Global Ratings has recently upgraded its issue-level rating on the Company's senior unsecured debt to ‘BB-' from ‘B+' and revised its recovery rating to ‘4' from ‘5.' S&P Global Ratings highlighted that the upgr.

Bausch + Lomb Corporation ( BLCO ) Bausch + Lomb Corporation - Analyst/Investor Day November 13, 2025 8:30 AM EST Company Participants Brenton Saunders - CEO & Chairman of the Board Osama Eldessouky - Executive VP & CFO Yehia Hashad - Executive VP of Research & Development and Chief Medical officer John Ferris - President of Consumer Mayssa Attar Andrew Stewart - President of Global Pharmaceuticals & International Consumer Yang Yang - President of Vision Care Bryan Reed Luc Bonnefoy - President of Surgical Kelly Swaim Cathleen McCabe Eric Donnenfeld Mark Schaeffer Lejla Vajzovic Conference Call Participants William Trattler Lejla …

The Simplify Aggregate Bond ETF offers US investment-grade bond exposure with a derivatives overlay for extra return and downside protection. AGGH's active strategy and hedging justify its higher 0.30% expense ratio but also result in higher volatility than traditional bond index funds. Current market conditions—compressed investment-grade spreads, widening high-yield spreads, and money market liquidity tensions—suggest caution for new investments in AGGH.

XP Inc.A (XP) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.39 per share a year ago.

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026.

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of James Hardie Industries plc (NYSE: JHX) between May 20, 2025 through August 18, 2025, both dates inclusive (the "Class Period") of the important December 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased James Hardie common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Wall Street and Hollywood have been captivated by the bidding war for one of media's most prize possessions.

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Freeport-McMoRan Inc. (NYSE: FCX) between February 15, 2022 and September 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

“I will tell you that nobody has done what we've done in terms of pricing,” Trump argued.

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

In the closing of the recent trading day, AeroVironment (AVAV) stood at $283.66, denoting a -2.59% move from the preceding trading day.

The latest trading day saw FedEx (FDX) settling at $264.73, representing a -1.06% change from its previous close.

In the most recent trading session, Samsara Inc. (IOT) closed at $36.45, indicating a -3.6% shift from the previous trading day.

In the closing of the recent trading day, Dollar General (DG) stood at $103.15, denoting a -1.1% move from the preceding trading day.